JERUSALEM, Jan. 7, 2025
/PRNewswire/ -- Senseera, a liquid biopsy company pioneering
chromatin epigenomics, announced the successful close of a
$7.1 million seed funding round led
by Lightspeed Venture Partners, with participation from I-Next
Capital and the Lowy Medical Research Institute.
The funding will advance Senseera's GEM BIOMARKERS™
liquid biopsy platform, powered by cfChIP-seq technology.
The platform decodes cell-specific gene expression and cell states
from a simple blood draw, providing detailed molecular insights for
diagnosing and monitoring diseases. This transformative approach
delivers the precision of biopsy-level insights with the
convenience of a non-invasive blood test.
Senseera's technology is built on decades of research led by
Prof. Nir Friedman and validated in
top-tier journals such as Nature Biotechnology. Supported by
data from over 20,000 human samples, Senseera has established a
robust foundation for accelerating drug development and precision
medicine in oncology, immunology, and metabolic diseases, and
revolutionizing liver diseases management. Liver diseases represent
a significant global health challenge, affecting up to 25% of the
population. Existing diagnostics often rely on invasive and risky
biopsies or non-specific tests, resulting in delayed diagnoses and
suboptimal patient care. Senseera's platform offers an innovative
solution for early detection and management of conditions like
MASLD/MASH, liver transplant rejection, and hepatocellular
carcinoma (HCC). The funds will accelerate market entry of
Senseera's next generation transplant rejection test, advance
clinical trials, and expand partnerships with global biopharma.
In addition to its unique liver diseases diagnostics pipeline,
Senseera's platform offers unparalleled potential for accelerating
drug development in cancer and immune disorders. By providing
simultaneous solid tissue and immune cell states monitoring, the
platform provides insights into tissue/tumor immune cross-talk,
enabling researchers and clinicians to better understand the
underlying mechanisms and support personalized treatments.
"This funding marks a major milestone in Senseera's journey
to transform diagnostics for liver diseases and beyond, and to
accelerate drug development," said Dr. Ronen Sadeh, CEO of Senseera. "With the
support from Lightspeed and our investors, we will advance clinical
trials, strengthen collaborations with global pharma leaders, and
expand our pipeline to improve patient outcomes."
About Senseera
Senseera is a next-generation liquid
biopsy company pioneering chromatin epigenomics to deliver deeper
disease insights. Its GEM BIOMARKERS™ platform enables
non-invasive detection and monitoring of diseases, advancing
personalized medicine through cutting-edge science and robust
molecular analysis.
Contact: info@senseerahealth.com
Logo - https://mma.prnewswire.com/media/2591678/Senseera.jpg
Logo - https://mma.prnewswire.com/media/2591679/Lightspeed.jpg
View original
content:https://www.prnewswire.com/news-releases/senseera-raises-7-1-million-seed-round-led-by-lightspeed-venture-partners-302343394.html
SOURCE Senseera
